LYNDHURST N.J., Jan. 18, 2018 /PRNewswire/ -- In relation to the recently announced decision by the Patent Trial and AppealBoard ("PTAB") on Amerigen Pharmaceuticals Limited's inter partes review (IPR2016-00286), challenging U.S. Patent 8,822,438 B2 (owned by Janssen Oncology, Inc.), John Lowry, Amerigen's President & CEO commented
Amerigen was represented during the hearings on IPR2016-00286 by William Hare of McNeely Hare & War LLP.
ZytigaŽ is a trademark of Janssen.
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.
View original content:http://www.prnewswire.com/news-releases/amerigens-petition-leads-to-us-zytiga-patent-invalidation-300585027.html
SOURCE Amerigen Pharmaceuticals
Subscribe to our Free Newsletters!